The DOI matches its Crossref record; 18 of the 20 references it cites were found in a registry or an index.
Do the Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, And Quality of Life Persist Six Months after Treatment in Intermediate-Frail and Frail Elderly Men?
Abstract
Context: Short-term testosterone (T) treatment in frail elderly men improves muscle mass and strength. It is unclear whether these effects can be maintained post treatment. Objective: To assess the durability of androgen effects in frail men. Design and Setting: Single center, randomized, double-blind, placebo-controlled trial to investigate the effects of 6 months T (25–75 mg daily) on muscle strength, body composition, physical function, and quality of life (QoL). Participants were assessed at the end of treatment (6 months) and 6 months after treatment cessation (12 months). Participants: 274 intermediate-frail and frail elderly men aged 65–90 years with low T levels. Results: Mean T increased from 11.1 (3.1) nmol/liter at baseline to 18.4 (3.5) nmol/liter at 6 months, then declined to 10.5 (3.7) nmol/L at 12 months, in the T-treated group. Isometric knee extension peak torque increased in the T-treated group compared with placebo to give an adjusted mean difference (95% CI) between groups of 8.1 (−0.2 to 16.5) Nm at 6 months. Lean mass increased in the T-treated group giving a difference between groups of 1.2 (0.8 to 1.7) kg at 6 months. Somatic and sexual symptoms improved during treatment. None of these differences between groups remained at 12 months. Prostate specific antigen (PSA) levels and haematocrit increased slightly during treatment but returned to baseline by 12 months. Conclusion: The effects of 6-month T treatment on muscle strength, lean mass, and QoL in frail men are not maintained at 6 months post treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis of testosterone supplementation found effect sizes of 0.47 (95% CI 0.12–0.84) for upper and 0.63 (95% CI 0.03–1.28) for lower extremity strength417, without sustained improvements in body composition418.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [418]
In the citing paper
“Although testosterone supplementation presents a clear physiological rationale, particularly for increasing muscle strength and function, the available data regarding the impact of testosterone administration on muscle function and mass remain limited and conflicting (87, 88).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [87]
In the citing paper
“This suggests, consistent with other studies, 103,104 that testosterone treatment needs to be given long term to maintain benefits.”
From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [103]
Citations
Cites
Frailty in Older Adults: Evidence for a Phenotype
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W. J., Burke, G., et al. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.3.m146 · Cited by 24,907 · cited 7×
“Frailty describes an age-related state of increased vulnerability, presaging adverse outcomes (1, 2).”
BackgroundMethodInfluentialLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 1×
“T levels decline with aging (6, 7) and may contribute to the age-related physical deterioration in the elderly (8, 9).”
BackgroundFeldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861 · cited 1×
“T levels decline with aging (6, 7) and may contribute to the age-related physical deterioration in the elderly (8, 9).”
BackgroundThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728 · cited 1×
“Since the use of T in elderly men often raises concern regarding adverse effects (14, 15), it would be important to determine whether short-term treatment can lead to prolonged benefits beyond the duration of T exposure.”
BackgroundAdverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713 · cited 1×
“There have been concerns about the health risks associated with the use of T in the elderly (14, 18).”
BackgroundSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629
Self-citationPage, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment
Grossmann, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0118 · Cited by 350
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
“Although testosterone supplementation presents a clear physiological rationale, particularly for increasing muscle strength and function, the available data regarding the impact of testosterone administration on muscle function and mass remain limited and conflicting (87, 88).”
BackgroundCorona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0262 · Cited by 217
Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment
Huhtaniemi, I. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122336 · Cited by 204
The Frailty Syndrome: A Comprehensive Review
Heuberger, R. A. (2011) · Journal of Nutrition in Gerontology and Geriatrics · doi:10.1080/21551197.2011.623931 · Cited by 185
Hypogonadism and male obesity: Focus on unresolved questions
Grossmann, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13723 · Cited by 164
Aging and the Male Reproductive System
Kaufman, J., Lapauw, B., Mahmoud, A., T'Sjoen, G. G., & Huhtaniemi, I. T. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00178 · Cited by 166
Hackett, G. I., Kirby, M. G., Edwards, D., Jones, T. H., Wylie, K. R., Ossei‐Gerning, N., David, J., & Muneer, A. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2017.10.067 · Cited by 158
“For treatment duration, in 2 RCTs involving 447 men 45 to 90 years old, cessation of T therapy resulted in relapse and reversal of benefits within 6 months, so it is likely to be required life long.(47,135)”
MethodHildreth, K. L., Barry, D. W., Moreau, K. L., Vande Griend, J., Meacham, R. B., Nakamura, T., Wolfe, P., Kohrt, W. M., Ruscin, J. M., Kittelson, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3695 · Cited by 140
“24 All other nonserious adverse events Total 9 (12) 13 (13) 6 (6) 7 (7) .”
Strandberg, T. E., Pitkälä, K. H., & Tilvis, R. S. (2011) · European Geriatric Medicine · doi:10.1016/j.eurger.2011.08.003 · Cited by 167
“Weakness (sarcopenia/dynapenia) [91,97,99,154–157]:”
New understanding of the pathogenesis and treatment of stroke-related sarcopenia
Li, W., Yue, T., & Liu, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110721 · Cited by 134
Is It Time to Begin a Public Campaign Concerning Frailty and Pre-frailty? A Review Article
Sacha, J., Sacha, M., Soboń, J., Borysiuk, Z., & Feusette, P. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00484 · Cited by 129
Testosterone deficiency in the aging male
McBride, J. A., Carson, C. C., & Coward, R. M. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215612961 · Cited by 117
Kaur, H., & Werstuck, G. H. (2021) · CJC Open · doi:10.1016/j.cjco.2021.05.007 · Cited by 114
“These results were not replicated in a later trial with a similar population and testosterone-administration technique.(31) Both the Vigen et al.”
ResultMale late-onset hypogonadism: pathogenesis, diagnosis and treatment
Huhtaniemi, I., & Forti, G. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.47 · Cited by 88
Garrido, J. F., Ruiz-Ros, V., Buigues, C., Navarro-Martínez, R., & Cauli, O. (2014) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2014.02.008 · Cited by 107
“results among studies (O’Connell et al., 2011).”
Current pharmacotherapies for sarcopenia
Hardee, J. P., & Lynch, G. S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1622093 · Cited by 92
“cle strength and functional capacity in frail elderly men [69].”
BackgroundObesity as a premature aging phenotype — implications for sarcopenic obesity
Nunan, E. L., Wright, C. L., Semola, O. A., Subramanian, M., Balasubramanian, P., Lovern, P. C., Fancher, I. S., & Butcher, J. T. (2022) · GeroScience · doi:10.1007/s11357-022-00567-7 · Cited by 88
Testosterone and Vascular Function in Aging
Alves-Lopes, R., Neves, K. B., Carneiro, F. S., & Tostes, R. C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00089 · Cited by 95
“…hemodynamic parameters, cognitive and sexual function, mood, muscle mass and strength), the beneficial effects may not be maintained (the gain of muscle mass, strength, and quality of life are not maintained at 6 months post-treatment with testosterone in frail elderly men; O’Connell et al., 2011).”
BackgroundDiem, S. J., Greer, N. L., MacDonald, R. H., McKenzie, L. G., Dahm, P., Ercan-Fang, N. G., Estrada, A., Hemmy, L. S., Rosebush, C. E., Fink, H. A., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-0830 · Cited by 78
“Overall, 6 fractures were reported in testosterone groups and 8 in placebo groups during treatment periods ranging from 6 to 24 months (31, 48, 61, 65, 71, 74, 75, 79, 80).”
BackgroundStorer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70
Advances in research on pharmacotherapy of sarcopenia
Feike, Y., Liu, Z., & Chen, W. (2021) · Aging Medicine · doi:10.1002/agm2.12168 · Cited by 82
Dias, J. P., Melvin, D., Simonsick, E. M., Carlson, O., Shardell, M. D., Ferrucci, L., Chia, C. W., Basaria, S., & Egan, J. M. (2016) · Andrology · doi:10.1111/andr.12126 · Cited by 65
“The increase in muscle strength of >5 N-min in our study has been associated with improved physical function (Kenny et al., 2010; Srinivas-Shankar et al., 2010; O’Connell et al., 2011).”
BackgroundEichholzer, M., Barbir, A., Basaria, S. S., Dobs, A. S., Feinleib, M., Güallar, E., Menke, A., Nelson, W. G., Rifai, N., Platz, E. A., et al. (2012) · The Aging Male · doi:10.3109/13685538.2012.705366 · Cited by 67
Do low testosterone levels contribute to ill-health during male ageing?
Yeap, B. B., de Araújo, A. B., & Wittert, G. (2012) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2012.725461 · Cited by 53
Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.10.001 · Cited by 48
Ng Tang Fui, M., Hoermann, R., Zajac, J. D., & Grossmann, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13385 · Cited by 37
Fode, M. M., Salonia, A., Minhas, S., Burnett, A. L. “., & Shindel, A. W. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.021 · Cited by 38
Brooke, J. C., Walter, D., Kapoor, D., Marsh, H., Muraleedharan, V., & Jones, T. H. (2014) · Andrology · doi:10.1111/j.2047-2927.2013.00177.x · Cited by 37
“Recent evidence has shown that short-term TRT improve muscle strength, lean mass and QoL (O’Connell et al., 2011) however, no long-term placebo-controlled trials have yet been published.”
BackgroundEffects of health care interventions on quality of life among frail elderly: a systematized review
van Rijckevorsel-Scheele, J., Willems, R., Roelofs, P. D. D. M., Koppelaar, E., Gobbens, R. J. J., & Goumans, M. J. B. M. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s190425 · Cited by 41
“08).(19,20) Favela et al(31) examined the effect of 1) weekly nurse home visits in combination with alert buttons and 2) only nurse home visits, and reported that none of the interventions had a statistically significant effect on quality of life.”
BackgroundPharmaceutical Interventions for Frailty and Sarcopenia
Laosa, O., Alonso, C., Castro, M., & Rodríguez‐Mañas, L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660705 · Cited by 33
“O ́Conell et al [99] Randomized and”
BackgroundSarcopenia in chronic kidney disease: from bench to bedside
Kim, D. W., & Song, S. H. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.338 · Cited by 39
“Several trials involving testosterone have consistently shown a positive effect of the drug in increasing muscle mass and function in older male patients [83-86].”
Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome
Tolrà, J. R., Barreda, J. T., del Río, L., Gregorio, S. D., & Miranda, E. F. (2013) · The Aging Male · doi:10.3109/13685538.2013.839648 · Cited by 28
Role of testosterone in cognition and mobility of aging men
Kaufman, J., & Lapauw, B. (2020) · Andrology · doi:10.1111/andr.12872 · Cited by 32
Androgen deficiency and type 2 diabetes mellitus
Gibb, F. W., & Strachan, M. W. J. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.04.004 · Cited by 31
Hormones and health outcomes in aging men
Yeap, B. B. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.012 · Cited by 30
Wu, B. W., Lorezanza, D., Badash, I., Berger, M., Lane, C. J., Sum, J. C., Hatch, G. F. R., & Schroeder, E. T. (2017) · Orthopaedic Journal of Sports Medicine · doi:10.1177/2325967117722794 · Cited by 28
“The upper age limit was established to increase the probability that the study participants would be eugonadal.(11,22,36,42,43) Inclusion criteria were (1) a history of trauma to a previously uninjured knee within the preceding 8 months, (2) ACL insufficiency as determined by a clinical examination, and (3) a score of…”
BackgroundBauman, W. A., Fountaine, M. F. L., Cirnigliaro, C. M., Kirshblum, S., & Spungen, A. M. (2014) · Journal of Spinal Cord Medicine · doi:10.1179/2045772314y.0000000206 · Cited by 24
Testosterone and cardiovascular risk—deciphering the statistics
Morgentaler, A., & Kacker, R. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.24 · Cited by 24
GREEN, D. J., Chasland, L. C., Yeap, B. B., & Naylor, L. H. (2024) · Sports Medicine - Open · doi:10.1186/s40798-024-00703-x · Cited by 34
“Although perhaps unsurprising, it is important to note that, following cessation of T treat - ment, muscular strength levels may not be maintained (unless otherwise targeted) [118], and the rate of strength loss may be correlated with the length of the antecedent T administration period [82].”
BackgroundPark, M. G., Cho, D.-Y., Yeo, J. K., Cho, S. I., Jung, J., Yang, S., Kong, D.-H., Ha, J. K., & Kim, J.-D. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.184269 · Cited by 23
Emerging drug therapies for frailty
Jeffery, C. A., Shum, D. W. C., & Hubbard, R. E. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.10.010 · Cited by 27
Testosterone, frailty and physical function in older men
Hsu, B., Cumming, R. G., & Handelsman, D. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1475227 · Cited by 25
“Nevertheless, the effects of 6 months of T treatment in those pre-frail and frail older men was not maintained at 6 months post treatment [61].”
BackgroundAndrogens and prostate disease
Page, S., & Cooper, L. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122361 · Cited by 29
“However, when this same group was followed up six months post T therapy, these effects were not maintained (21).”
BackgroundAndrogen Deficiency as a Biological Determinant of Frailty: Hope or Hype?
Afilalo, J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12835 · Cited by 21
“The observation that androgen therapy leads to gains in muscle strength and function and that these gains revert after discontinuation of therapy support a causal link between low testosterone and frailty.(29) Moreover, androgen deficiency in younger men with hypogonadism(30) and androgen deprivation therapy in men wi…”
BackgroundDiagnosis and Treatment of Low Testosterone among Patients with End‐Stage Renal Disease
Bao, Y., & Johansen, K. L. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12318 · Cited by 21
“A follow-up at 12 months showed that none of the gains in body composition, muscle strength or physical function persisted 6 months after treatment ended (28).”
BackgroundThe role of mitochondria in longevity and healthspan
Brand, M. D. (2014) · Longevity & Healthspan · doi:10.1186/2046-2395-3-7 · Cited by 17
“This is addressed by Velarde [29], who discusses the evidence that poorer healthspan is associated with declining circulating levels of these hormones [30-32].”
BackgroundUK policy statements on testosterone deficiency
Hackett, G. I., Kirby, M. G., Edwards, D., Jones, T. H., Rees, J., & Muneer, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12901 · Cited by 19
Low testosterone in ageing men: a modifiable risk factor for frailty?
O’Connell, M. D. L., Ravindrarajah, R., Tajar, A., & Wu, F. C. W. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.08.003 · Cited by 16
Self-citationInternational spinal cord injury endocrine and metabolic extended data set
Bauman, W. A., Wecht, J. M., & Biering‐Sørensen, F. (2017) · Spinal Cord · doi:10.1038/sc.2016.164 · Cited by 13
Handelsman, D. J., Grossmann, M., Yeap, B. B., Stuckey, B. G. A., Shankara‐Narayana, N., Conway, A. J., Inder, W. J., McLachlan, R. I., Allan, C. A., Jenkins, A. J., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad485 · Cited by 12
Functional capacity, sarcopenia, and bone health
Laskou, F., Patel, H. P., Cooper, C. C., & Dennison, E. M. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101756 · Cited by 17
Wu, B. W., Berger, M., Sum, J. C., Hatch, G. F. R., & Schroeder, E. T. (2014) · BMC Surgery · doi:10.1186/1471-2482-14-102 · Cited by 11
Braga, M. A. P., Rivera, A., Marinheiro, G., Felix, N. S., Carvalho, P. E. P., Gewehr, D. M., Teixeira, L., Clemente, M. R. C., Reis, P. C. A., de Amorim, L. G. C. R., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00737-w · Cited by 10
Testosterone Therapy for Prevention and Treatment of Obesity in Men
Caliber, M., & Saad, F. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0010 · Cited by 11
“However, at month 96, total and free T levels had dropped to 372 and 8.68 ng/dL respectively, with body fat % no longer being significantly different from baseline, 103 suggesting inadequate dosing/adherence to TTh. –106 Suboptimal TTh also occurs in randomized controlled trials.”
InfluentialPerspectives for metabolomics in testosterone replacement therapy
Haring, R. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0119 · Cited by 13
How to Prevent Loss of Muscle Mass and Strength among Older People in Neuro-Rehabilitation?
Lathuilière, A., Mareschal, J., & Graf, C. E. (2019) · Nutrients · doi:10.3390/nu11040881 · Cited by 10
“As testosterone doesn’t seem to improve function in such a setting, and as their effect is reversible also for the beneficial effect on muscle mass [50], it doesn’t seem to be reasonable to propose this treatment after a stroke.”
BackgroundConnolly, M. J., Kerse, N. M., WILKINSON, T. J., Menzies, O. H., Rolleston, A. K., Chong, Y. H., Broad, J., Moyes, S. A., Jatrana, S., & Teh, R. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016572 · Cited by 8
Self-citationBabcock, M. C., DuBose, L. E., Hildreth, K. L., Stauffer, B. L., Cornwell, W. K., Kohrt, W. M., & Moreau, K. L. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00245.2022 · Cited by 10
Update on the safety of testosterone therapy in cardiac disease
Aaronson, A. J., Morrissey, R. P., Nguyen, C. T., Willix, R., & Schwarz, E. R. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.566213 · Cited by 9
“However, this study was not powered to detect this difference [37].”
BackgroundAnaissie, J. E., Pastuszak, A. W., & Khera, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00012-3 · Cited by 9
Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism)
Saad, F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_23 · Cited by 8
“a geriatric population of frail elderly men, where muscle mass and strength increased during 6 months of T therapy, but these effects were lost after cessation of treatment during the following 6 months (O’Connell et al. 2011).”
BackgroundCaliber, M., & Hackett, G. I. (2019) · The Aging Male · doi:10.1080/13685538.2018.1549211 · Cited by 7
Allan, C. A., & McLachlan, R. I. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00139-8 · Cited by 5
Kaufman, J., T'Sjoen, G. G., & Vermeulen, A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.017 · Cited by 3
Orexigenic Agents in Geriatric Clinical Practice
Viswambharan, V., Manepalli, J. N., & Grossberg, G. T. (2013) · Aging Health · doi:10.2217/ahe.12.83 · Cited by 3
Allan, C. A., & McLachlan, R. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00139-6 · Cited by 7
Age-Related Testosterone Decline: Whom Do We Treat and Why?
Ahmad, A. E., Bruha, M., & Welliver, C. (2016) · Current Sexual Health Reports · doi:10.1007/s11930-016-0074-1 · Cited by 2
Topical Testosterone Gel for the Treatment of Male Hypogonadism
Udeoji, D. U., Phan, A., Katsiyiannis, P., Willix, R., & Schwarz, E. R. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s7348 · Cited by 2
Benefits and Risks of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M., & Morgentaler, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813197-8.00018-x · Cited by 2
Kuznetsov, K. D., & Marchenkova, L. (2024) · Bulletin of Rehabilitation Medicine · doi:10.38025/2078-1962-2024-23-4-92-100 · Cited by 1
Impact of Testosterone Deficiency and Testosterone Therapy on Men’s Health
Traish, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_13 · Cited by 1
Pollock, N. K. (2012) · IBMS BoneKEy · doi:10.1038/bonekey.2012.25 · Cited by 1
Anabole und molekulare Interventionen am Muskel: Sinnvolle Anti-Aging-Strategie?
Münzer, T. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1299-y · Cited by 1
Plasma Testosterone and Dihydrotestosterone as Markers of Heart Disease and Mortality in Older Men
Yeap, B. B. (2016) · Springer eBooks · doi:10.1007/978-94-007-7678-4_38 · Cited by 1
Predictive Factors of Efficacy Maintenance after Testosterone Treatment Cessation
Park, M. G., Yeo, J. K., Park, S., Na, W., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020151 · Cited by 2
“In contrast, another study reported that, in frail elderly men, muscle strength and physical function were not maintained, but rather deteriorated with a decrease of TT, after the cessation of a six-month course of TRT [27].”
ResultAge-Related Testosterone Deficiency Merits Treatment
Traish, A. M. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0019 · Cited by 4
The Interplay of Muscle and Bone in Later Life
Laskou, F., Dennison, E. M., & Patel, H. P. (2021) · Springer eBooks · doi:10.1007/978-3-030-78128-6_10 · Cited by 2
Prostate- Specific Antigen (PSA) Significance in Frail MenPreprint
Κωστακόπουλος, Ν., Bellos, T. C., Katsimperis, S. N., Malovrouvas, E., & Papatsoris, A. (2023) · Preprints.org · doi:10.20944/preprints202308.1224.v1
Prostate- Specific Antigen (PSA) Significance in Frail and Sarcopenic MenPreprint
Κωστακόπουλος, Ν., Bellos, T. C., Katsimperis, S. N., Malovrouvas, E., & Papatsoris, A. (2024) · Preprints.org · doi:10.20944/preprints202308.1224.v2
Metabolomics for the Individualized Therapy of Androgen Deficiency Syndrome in Male Adults
Haring, R., Budde, K., & Wallaschofski, H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1689-0_10
Gérvas, J., Moral, E. G., & Gorricho, J. (2013) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(13)70669-8
Plasma Testosterone and Dihydrotestosterone as Markers of Heart Disease and Mortality in Older Men
Yeap, B. B. (2015) · Springer eBooks · doi:10.1007/978-94-007-7741-5_38-1
Fui, M. N. T., & Mark, A. (2017) · Minerva Access (University of Melbourne) · Cited by 1
Vieillissement, modifications hormonales, et vulnérabilité psychique
Duval, F. (2020) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2019.12.002
Hypogonadism and Testosterone Therapy in Elderly Men
Yeap, B. B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66168-8
Yassin, A. A., Albaba, B., Talib, R., Aboumarzouk, O., Alwani, M., & Arous, M. M. (2022) · Current Trends in Internal Medicine · doi:10.29011/2638-003x.100063 · Cited by 2
“This confirms previous findings showing that continuous testosterone therapy is required for achievement and maintenance of health benefits of testosterone therapy, as benefits disappear after discontinuation of testosterone therapy [18-24].”
ResultTestosterone Therapy in Oncologic Patients
Solsrud, E., Louters, M. M., & Pearlman, A. M. (2023) · Current Sexual Health Reports · doi:10.1007/s11930-022-00351-w
Diagnosis and Treatment of Stroke-related Sarcopenia: A Narrative reviewarticle
Chen, S.-H. (2022) · Rehabilitation practice and science · doi:10.6315/tjpmr.202212_50(2).0002
Hypogonadism and testosterone therapy in elderly men
Yeap, B. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00046-7
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01141-9 · Cited by 1
“…men a reported that 6-mo Tes treatment ↑ lean mass, knee extension and QoL during treatment, but effects were not sustained 6 mo after withdrawal [13] In a phase 4 RCT, 176 men a with mobility limitations and low Tes levels experienced significantly ( p < 0.003) ↑ maximal voluntary muscle…”
InfluentialSarkopene Adipositas im Alter: Ursachen, Folgen und Behandlungsansätze
Rippl, M., Drey, M., & Schluessel, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9415
“Bei Patient*innen mit einer Tumorkachexie konnte jedoch kein eindeutiger Effekt einer NSAR-Therapie auf die Muskulatur nachgewiesen werden [53] wohingegen in einer Kohorte geriatrischer Männer eine Zunahme der Muskelmasse unter COX-Inhibitor Einnahme verzeichnet wurde [54].”
Long-Term Effects of Testosterone Therapy in Men with Testosterone Deficiency
Saad, F., & Caliber, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_17
Principles of diet therapy for sarcopenic obesity: A review
Pavlovskaya, E. V., Кislyak, O. A., & Starodubova, A. V. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.07.203270 · Cited by 2
Prostate-specific antigen significance in frail men
Κωστακόπουλος, Ν., Bellos, T. C., Katsimperis, S. N., Manolitsis, I. S., Tzelves, L. I., Malovrouvas, E., & Papatsoris, A. (2026) · Hellenic Urology · doi:10.23736/s2241-9136.25.00065-9
Qin, H., Zuo, D., Wang, Z., Li, L., Zuo, L., Lv, Y., Tu, S., Wang, J., Chen, Y., Li, X., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04773-7
“For instance, another study found no significant increase in cardiovascular events with medium exposure to exogenous testosterone in frail elderly men [106].”
Gonadal Hormones, Diseases, and Emerging Therapeutics
Mirza, F., Zakko, L., & Taxel, P. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2745-1_3 · Cited by 1
Metadata
- Authors
- O'Connell, M. D. L., Roberts, S. A., Srinivas-Shankar, U., Tajar, A., Connolly, M. J., Adams, J. E., Oldham, J. A., & Wu, F. C. W.
- Affiliations
- Andrology Research Unit, Developmental & Regenerative Biomedicine Research Group (M.D.L.O., U.S.-S., F.C.W.W.), Manchester Academic Health Science Centre, Manchester Royal Infirmary, The University of Manchester, Manchester, United Kingdom M13 9WL;
- Manchester Academic Health Science Centre (GB)
- University of Auckland (NZ)
- University of Manchester (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02-01
- Volume
- 96
- Issue
- 2
- Pages
- 454-458
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2007908928
- Cited by
- 98
- References
- 20
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 9 · 2018: 4 · 2017: 11 · 2016: 3 · 2015: 5 · 2014: 12 · 2013: 4 · 2012: 12
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
- Keywords
- testosterone replacement therapy, androgen deficiency, muscle strength, lean body mass, body composition, physical function, quality of life, treatment durability, post-treatment follow-up, prostate-specific antigen, hematocrit
- MeSH terms
- Aged, Aged, 80 and over, Body Composition, Double-Blind Method, Hematocrit, Humans, Isometric Contraction, Luteinizing Hormone, Cholesterol, HDL, Male, Motor Activity, Quality of Life, Sexual Behavior, Sex Hormone-Binding Globulin, Testosterone, Absorptiometry, Photon, Frail Elderly, Treatment Outcome, Prostate-Specific Antigen, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.